A method for treating a disorder using an automatic injection device is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a syringe actuation component for moving the syringe
A method for treating a disorder using an automatic injection device is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a syringe actuation component for moving the syringe towards a first open end of the housing such that the needle projects from the first end, and for subsequently applying pressure to the bung. The syringe actuation component includes a pressurizer, a rod comprising a compressible portion projecting therefrom, and a flange between a second end of the rod and the compressible portion. The device also includes a biasing mechanism for biasing the syringe actuation component towards the first open end of the housing, the biasing mechanism disposed about the second end of the rod between the flange and a second end of the housing.
대표청구항▼
1. A method for treating a disorder in which TNFα activity is detrimental in a subject, the method comprising: using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end;biasing
1. A method for treating a disorder in which TNFα activity is detrimental in a subject, the method comprising: using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end;biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe disposed in the housing towards the first end of the housing such that a hollow needle in fluid communication with a syringe barrel holding the adalimumab projects from the first end and for subsequently applying pressure to a bung sealing the syringe barrel to force the adalimumab through the hollow needle;wherein the syringe actuation component comprises a pressurizer, at a first end of the syringe actuation component, for selectively applying pressure to the bung, a rod comprising a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded position prior to entering the barrel portion of the syringe and a second compressed position for initiating movement of the bung and a flange between a second end of the syringe actuation component and the compressible portion; andwherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing. 2. The method of claim 1, wherein the disorder is any one of the following: rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, ulcerative colitis, Crohn's disease, juvenile rheumatoid arthritis, hidradenitis suppurativa, uveitis, nail psoriasis, pediatric Crohn's disease, pediatric ulcerative colitis, or pediatric psoriasis. 3. The method of claim 1, wherein the automatic injection device further comprises an activation button coupled to the housing for actuating the syringe actuation component. 4. The method of claim 3, wherein the automatic injection device further comprises a latch for latching the syringe actuation component in a retracted position prior to actuation by the activation button. 5. The method of claim 1, wherein the automatic injection device further comprises a window on the housing for viewing the interior of the housing. 6. The method of claim 5, wherein the window has a substantially key-hole shape. 7. The method of claim 5, wherein the window includes a fill line at a position in the window for indicating a full dose of the adalimumab. 8. The method of claim 1, wherein the automatic injection device further comprises an indicator for indicating when the syringe is empty. 9. The method of claim 1, wherein the automatic injection device further comprises a removable cap for covering one of the first end of the housing or the second end of the housing. 10. The method of claim 1, wherein the automatic injection device further comprises a needle sheath that advances over the needle projecting through the first end after ejection of the adalimumab from the syringe. 11. The method of claim 1, wherein the compressible portion extends along a longitudinal length of the rod between a lower solid portion of the rod forming the pressurizer and an upper solid portion of the rod. 12. The method of claim 1, wherein the compressible portion comprises: a central void extending at least along a portion of the syringe actuation component; andone or more flexible elbows provided on either side of the central void, wherein the one or more elbows project radially outwardly from the central void when the compressible portion is in the first expanded position, and wherein the one or more elbows are collapsed radially inwardly toward the central void when the compressible portion is in the second compressed position. 13. The method of claim 1, wherein the flange is configured to hold the first biasing mechanism in a compressed position until actuation of the automatic injection device. 14. The method of claim 1, wherein the syringe actuation component further comprises: a base extending distally from the flange toward the second end of the housing, the base configured to support the first biasing mechanism. 15. The method of claim 14, wherein the base comprises: one or more flexible legs around which the first biasing mechanism coils. 16. A method for treating a disorder in which TNFα activity is detrimental in a subject, the method comprising: using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end;biasing a plunger in the housing with a biasing mechanism towards the open first end of the housing;wherein the plunger comprises a rod configured to be connected or adjacent at a first end to a bung of a syringe, a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded inactivated position and a second compressed activated position for initiating movement of the bung, and a flange between a second end of the rod and the compressible portion; andwherein the biasing mechanism is disposed about the second end of the rod between the flange and the second end of the housing. 17. The method of claim 16, wherein the automatic injection device further comprises an activation button coupled to the housing for actuating the plunger. 18. The method of claim 17, wherein the automatic injection device further comprises a latch for latching the plunger in a retracted position prior to actuation by the activation button. 19. The method of claim 16, wherein the automatic injection device further comprises a window on the housing for viewing the interior of the housing. 20. The method claim of claim 16, wherein the disorder is any one of the following: rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, ulcerative colitis, Crohn's disease, juvenile rheumatoid arthritis, hidradenitis suppurativa, uveitis, nail psoriasis, pediatric Crohn's disease, pediatric ulcerative colitis, or pediatric psoriasis. 21. A method for treating a disorder in which TNFα activity is detrimental in a subject, the method comprising: using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end, a second end, a window disposed in a side wall for viewing the interior of the housing and indicator that aligns with the window when the adalimumab has been injected into the user;biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe movably disposed in the housing towards the open first end of the housing such that a hollow needle in fluid communication with the a barrel portion of the syringe holding the adalimumab projects from the open first end and for subsequently applying pressure to a bung sealing the barrel portion and selectively applying pressure to the adalimumab to force the adalimumab through the hollow needle;wherein the syringe actuation component comprises a rod having an upper solid portion having a first end, a lower solid portion having a second end operable to move the bung and to transmit an expulsion force thereto, and a projecting portion projecting from the rod along at least a portion of a length of the rod, the projecting portion comprising two or more flexible elbows on either side of a central void provided between the upper and lower solid portions and aligned along a central axis of the rod, the projecting portion having a first expanded position prior to entering the barrel portion of the syringe in which the flexible elbows project radially outwardly to form the central void, and the projecting portion having a second compressed position for applying the second end of the lower solid portion to the bung in which the flexible elbows are compressed radially inwardly toward the central void, and a flange disposed between the first end of the upper solid portion of the rod and the projecting portion of the rod;wherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing;wherein the housing comprises a second biasing mechanism for holding the syringe retracted in the housing until the first biasing mechanism is released; andremoving a first removable cap that covers the open first end of the housing or the second end of the housing. 22. The method claim of claim 21, wherein the disorder is any one of the following: rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, ulcerative colitis, Crohn's disease, juvenile rheumatoid arthritis, hidradenitis suppurativa, uveitis, nail psoriasis, pediatric Crohn's disease, pediatric ulcerative colitis, or pediatric psoriasis. 23. The method of claim 21, wherein the central void is a longitudinally extending slit. 24. The method of claim 21, wherein the housing is fixed relative to the syringe. 25. The method of claim 21, wherein the automatic injection device further comprises: an activation button coupled to the housing for actuating the syringe actuation component. 26. The method of claim 25, wherein the automatic injection device further comprises: a latch for latching the syringe actuation component in a retracted position prior to actuation by the activation button. 27. The method of claim 21, wherein the adalimumab is pre-loaded in the barrel portion of the syringe. 28. The method of claim 21, wherein the automatic injection device further comprises: a needle sheath configured to advance over the needle projecting through the open first end of the housing after ejection of the adalimumab from the syringe.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (270)
Groenke Allen W. ; Brewer James E., AED with force sensor.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Apparatus and methods for self-administration of vaccines and other medicaments.
Olson Kenneth F. (Minneapolis MN) Gilman Byron L. (Plymouth MN) Anderson Katherine H. (Golden Valley MN), Automated external defibrillator with lid activated self-test system.
Wilmot John G. ; Goldberg Jeffrey L. ; Page Jon ; Ketcham Cliff ; Castleberry Jeffrey P. ; Morton Jason ; Edsall Dave ; Boyd Robert R. ; Hill Robert L., Automatic injector.
Sarnoff Stanley J. (Bethesda MD) Tarello William R. (Bethesda MD) Lopez Claudio (Silver Spring MD) Karcher Daniel M. (Great Falls VA), Automatic medicament ingredient mixing and injecting apparatus.
Sarnoff Stanley J. (Bethesda MD) Tarello William R. (Bethesda MD) Lopez Claudio (Silver Spring MD) Karcher Daniel W. (Great Falls VA), Automatic medicament ingredient mixing and injecting apparatus.
Vargas Walter (c/o George Spector 3615 Woolworth Bldg. 233 Broadway New York NY 10007) Spector George (3615 Woolworth Bldg. ; 233 Broadway New York NY 10007), Automatic syringe plunger.
Sarnoff Stanley J. (Bethesda MD) Lopez Claudio (Gaithersburg MD) Dalling N. Lawrence (Cross Junction VA), Conveniently carried frequent use auto-injector with improved cap structure.
Pearson William R. (Laurel MD) Spady David Edward (Centreville VA) Lopez Claudio (Darnstown MD) Lee Hyung J. (Cary NC) Wilmot John G. (Germantown MD) Dalling N. Lawrence (Cross Junction VA), Dental cartridge assembly auto-injector with protective needle cover.
Koszinowski Ulrich H. (Tbingen DEX) Keil Gnther M. (Tbingen DEX) Dorsch-Hsler Karoline (Zrich CHX) Schaffner Walter (Weiningen CHX), Deoxyribonucleic acid segment from a virus.
Edwards, Eric Shawn; Edwards, Evan Thomas; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Devices, systems and methods for medicament delivery.
Edwards, Eric Shawn; Edwards, Evan Thomas; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Devices, systems and methods for medicament delivery.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Kriesel Marshall S. ; Kazemzadeh Farhad ; Kriesel Matthew B. ; Feng William W.. ; Barber Steve C. ; Kluck William J., Fluid delivery device with conformable ullage.
Garcia Fernando S. (Eden Prairie MN) Ginnow-Merkert Hartmut (Eden Prairie MN) Anderson Paul J. (Eden Prairie MN) Hudson Bertram J. (Eden Prairie MN), Glucose medical monitoring system.
Salfeld,Jochen G.; Allen,Deborah J.; Hoogenboom,Hendricus R. J. M.; Kaymakcalan,Zehra; Labkovsky,Boris; Mankovich,John A.; McGuinness,Brian T.; Roberts,Andrew J.; Sakorafas,Paul; Schoenhaut,David; Va, Human antibodies that bind human TNFα.
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M. ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Paul ;, Human antibodies that bind human TNF.alpha..
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M.,BEX ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Pa, Human antibodies that bind human TNF.alpha..
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut,, Human antibodies that bind human TNFa.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Kaplan Sheldon (Potomac MD) Calkins George B. (Bethesda MD) Sarnoff Stanley J. (Bethesda MD) Dalling N. Lawrence (Wheaton MD), Hypodermic injection device having means for varying the medicament capacity thereof.
Eigler,Neal L.; Whiting,James S., Implantable system and method for measuring left atrial pressure to detect, diagnose and treating congestive heart failure.
Gabriel Jochen (Stuttgart DEX) Bechtold Herbert (Ehningen DEX) Hambrecht Gerhard (Rosenberg-Sindolzheim DEX) Nothdurft Klaus (Stuttgart DEX), Injection device for injection, especially self-administered injection, of medicament, including mechanisms for nulling.
Morgan Carlton B. (Seattle WA) Yerkovich Daniel (Seattle WA) Lyster Thomas D. (Redmond WA) Hagen Eric C. (Kirkland WA) Roberts Douglas H. (Lynnwood WA), Interactive portable defibrillator.
Morgan Carlton B. (Seattle WA) Yerkovich Daniel (Seattle WA) Lyster Thomas D. (Redmond WA) Hagen Eric C. (Kirkland WA) Roberts Douglas H. (Lynnwood WA), Interactive portable defibrillator including ECG detection circuit.
Sagstetter William E. (2217 Grove St. Denver CO 80211) Wanderer Alan A. (3601 S. Pennsylvania Englewood CO 80110), Manually operated reusable injection apparatus.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A.; Williamson, IV, T. Spencer, Medical injector with compliance tracking and monitoring.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Medicament delivery device configured to produce an audible output.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Medicament delivery device having an electronic circuit system.
Maksymowych, Walter P.; Wong, Robert L., Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα.
Le Junming (Jackson Heights NY) Vilcek Jan (New York NY) Dadonna Peter (Palo Alto CA) Ghrayeb John (Thorndale PA) Knight David (Berwyn PA) Siegel Scott A. (Westborough MA), Methods of treating TNF-a
상세보기
Moeller Achim (Limburgerhof DEX) Emling Franz (Ludwigshafen DEX), Monoclonal antibodies against human tumor necrosis factor (TNF), and use thereof.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Haber Terry M. (El Toro CA) Smedley William H. (Lake Elsinore CA) Foster Clark B. (Laguna Niguel CA), Needle hiding shield for a dose metering syringe.
Sarnoff Stanley J. (Bethesda MD) Calkins George B. (Bethesda MD) Tarello William R. (Bethesda MD), Plural dosage automatic injector with improved safety.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Botich Michael J. (1307 Hanover Ct. Ventura CA 93003) Halseth Thor R. (1223 Village Ct. Simi Valley CA 93065), Retractable needle hypodermic syringe system.
McWethy, Robert T.; Barker, John; Botich, Michael J.; Halseth, Thor R., Retractable needle medical device for injecting fluid from a pre-filled cartridge.
Haber Terry M. (Lake Forest CA) Foster Clark B. (Laguna Niguel CA) Smedley William H. (Lake Elsinore CA), Reusable pharmaceutical dispenser with full stroke indicator.
Stiles Donald E. (5860 McCoin Dr. Dryden MI 48428) Brakeman Randall M. (27390 Wellington Franklin MI 48025) Sherwin Dewayne J. (378 S. Sommers Rd. Imlay City MI 48444), Self-sheathing hypodermic syringe.
Moodie, Rachel; Hyland, Elizabeth, Methods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.